RUNX1 and metabolic dysfunction-associated steatotic liver disease: These results suggest that hepatic RUNX1 expression increases in the first steps of NAFLD, but in advanced stages of the disease, RUNX1 levels decrease, as if persistent inflammation induces the inhibition of the signaling pathway.